ALFA Filings
Every announcement, straight from the exchange
Every Gujarat Themis Biosyn earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements with these filters
GTBL reported strong Q1FY27 growth with 22.1% revenue and PAT increases, driven by sales volumes. Strategy is shifting toward becoming an integrated fermentation-led CDMO via major acquisitions and API forward integration.
GTBL reported strong Q1 FY27 results with 22.1% revenue growth and 49.4% EBITDA growth. Strategy focuses on global CDMO expansion through acquisitions and forward integration into API production.
GTBL is transforming into a global CDMO platform via acquisitions of MicroBiopharm Japan and Sanofi's anti-TB portfolio. FY26 revenue stood at INR 16,582 Lakhs with a 45.55% EBITDA margin.
Gujarat Themis Biosyn Limited reports Q4 FY26 revenue of ₹44.23 cr (+17.2% YoY) and PAT of ₹10.89 cr. Management announced two major inorganic acquisitions to pivot towards a CDMO model.
Gujarat Themis Biosyn (GTBL) announced the acquisition of 100% of MicroBiopharm Japan (MBJ) for JPY 21.5 Bn (~INR 1,300 Cr), transitioning GTBL into a globally integrated fermentation-based CDMO.